Wave Life Sciences Beheer
Beheer criteriumcontroles 3/4
De CEO Wave Life Sciences is Paul B. Bolno, benoemd in Dec2013, heeft een ambtstermijn van 10.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.87M, bestaande uit 16.4% salaris en 83.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde $ 3.81M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 8 jaar.
Belangrijke informatie
Paul B. Bolno
Algemeen directeur
US$3.9m
Totale compensatie
| Percentage CEO-salaris | 16.4% |
| Dienstverband CEO | 10.9yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 3.9yrs |
| Gemiddelde ambtstermijn bestuur | 8yrs |
Recente managementupdates
Recent updates
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst
Oct 16There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump
Sep 25
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
Sep 24Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
Sep 08We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate
Aug 05Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now
Jun 25We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
Sep 24Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$73m |
| Mar 31 2024 | n/a | n/a | -US$62m |
| Dec 31 2023 | US$4m | US$636k | -US$58m |
| Sep 30 2023 | n/a | n/a | -US$85m |
| Jun 30 2023 | n/a | n/a | -US$131m |
| Mar 31 2023 | n/a | n/a | -US$151m |
| Dec 31 2022 | US$3m | US$618k | -US$162m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$118m |
| Dec 31 2021 | US$4m | US$597k | -US$122m |
| Sep 30 2021 | n/a | n/a | -US$116m |
| Jun 30 2021 | n/a | n/a | -US$143m |
| Mar 31 2021 | n/a | n/a | -US$145m |
| Dec 31 2020 | US$1m | US$579k | -US$150m |
| Sep 30 2020 | n/a | n/a | -US$178m |
| Jun 30 2020 | n/a | n/a | -US$196m |
| Mar 31 2020 | n/a | n/a | -US$197m |
| Dec 31 2019 | US$4m | US$579k | -US$194m |
| Sep 30 2019 | n/a | n/a | -US$175m |
| Jun 30 2019 | n/a | n/a | -US$162m |
| Mar 31 2019 | n/a | n/a | -US$156m |
| Dec 31 2018 | US$6m | US$541k | -US$147m |
| Sep 30 2018 | n/a | n/a | -US$140m |
| Jun 30 2018 | n/a | n/a | -US$127m |
| Mar 31 2018 | n/a | n/a | -US$116m |
| Dec 31 2017 | US$3m | US$515k | -US$102m |
Compensatie versus markt: De totale vergoeding ($USD 3.87M ) Paul B. } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.36M ).
Compensatie versus inkomsten: De vergoeding van Paul B. is gestegen terwijl het bedrijf verliesgevend is.
CEO
Paul B. Bolno (50 yo)
10.9yrs
Tenure
US$3,874,300
Compensatie
Dr. Paul B. Bolno, M.D., MBA served as an Independent Director at SQZ Biotechnologies Company since June 2020 until March 2024. Since May 2020 he has served as Chairman of the Scientific Advisory Group for...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 10.9yrs | US$3.87m | 0.18% $ 3.8m | |
| CFO & Principal Accounting Officer | 3.9yrs | US$1.70m | 0.029% $ 635.7k | |
| Chief Technology Officer | 4.5yrs | US$1.78m | 0.12% $ 2.6m | |
| Chief Scientific Officer | less than a year | geen gegevens | geen gegevens | |
| Head of Investor Relations | 5.6yrs | geen gegevens | geen gegevens | |
| Senior VP & General Counsel | 8.5yrs | geen gegevens | geen gegevens | |
| Senior VP of Corporate Development & Head of Emerging Areas | 7.8yrs | US$1.68m | 0% $ 0 | |
| Senior VP & Head of Human Resources | 1.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Chemistry | 3yrs | geen gegevens | geen gegevens | |
| Chief Development Officer | 2.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Translational Medicine | 1.8yrs | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van WVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 10.6yrs | US$3.87m | 0.18% $ 3.8m | |
| Director | 11.3yrs | US$170.74k | 0.020% $ 426.0k | |
| Independent Director | 5.2yrs | US$194.74k | 0.078% $ 1.7m | |
| Independent Chairperson | 8yrs | US$222.24k | 0.085% $ 1.8m | |
| Independent Director | 7.8yrs | US$188.74k | 0.085% $ 1.8m | |
| Independent Director | 9.8yrs | US$170.74k | 0% $ 0 | |
| Independent Director | 12.3yrs | US$170.74k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$185.74k | 0.078% $ 1.7m | |
| Independent Director | 4.3yrs | US$172.24k | 0.069% $ 1.5m |
8.0yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van WVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).